Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
Daix (France), Long Island City (New York, United States), March 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported its full-year results for 2021.
Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “We are extremely proud of the strong progress of our clinical pipeline which has now two advanced clinical programs: a Phase III clinical trial in NASH with lanifibranor and a Phase IIb trial in patients with psoriasis initiated and fully financed by our partner AbbVie with cedirogant. Inventiva also announced the design of LEGEND, a Phase II combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes and we are looking forward to the results of our Phase II clinical trial in patients with type 2 diabetes and NAFLD expected in the second half of 2022. Furthermore, we believe the publication of our NATIVE Phase IIb clinical trial results by The New England Journal of Medicine strengthened the legitimacy of lanifibranor as a potential key treatment in NASH.
In addition, we have strengthened our financial position with existing and new institutional investors, notably with the sale of approximately $32 million of ADS via our ATM program in September. We have also received a €4 million milestone payment from our partner AbbVie, in connection with the cedirogant Phase IIb initiation, further supporting Inventiva’s cash position of €95.4 million as of December 31, 2021.“
Download PDF